Skip to main content
Top
Published in: Breast Cancer Research 1/2017

Open Access 01-12-2017 | Erratum

Erratum to: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells

Authors: Chun-Yu Liu, Ling-Ming Tseng, Jung-Chen Su, Kung-Chi Chang, Pei-Yi Chu, Wei-Tien Tai, Chung-Wai Shiau, Kuen-Feng Chen

Published in: Breast Cancer Research | Issue 1/2017

Login to get access

Excerpt

In the published article [1], the authors noticed an error to Fig. 1e in which the MTT curve of drug treatments (sorafenib, SC-1 and SC-43) in SK-BR3 cells was erroneously put as the same with that of HCC-1937 cells. …
Metadata
Title
Erratum to: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells
Authors
Chun-Yu Liu
Ling-Ming Tseng
Jung-Chen Su
Kung-Chi Chang
Pei-Yi Chu
Wei-Tien Tai
Chung-Wai Shiau
Kuen-Feng Chen
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2017
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-017-0800-2

Other articles of this Issue 1/2017

Breast Cancer Research 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine